EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors by Kostine, Marie et al.
  1Kostine M, et al. Ann Rheum Dis 2020;0:1–13. doi:10.1136/annrheumdis-2020-217139
Recommendation
EULAR points to consider for the diagnosis and 
management of rheumatic immune- related adverse 
events due to cancer immunotherapy with 
checkpoint inhibitors
Marie Kostine   ,1 Axel Finckh   ,2 Clifton O Bingham 3rd,3 Karen Visser,4 
Jan Leipe,5,6 Hendrik Schulze- Koops,6 Ernest H Choy,7 Karolina Benesova,8 
Timothy R D J Radstake,9 Andrew P Cope,10 Olivier Lambotte,11 
Jacques- Eric Gottenberg   ,12 Yves Allenbach   ,13 Marianne Visser,14 
Cindy Rusthoven,14 Lone Thomasen,15 Shahin Jamal,16 Aurélien Marabelle,17 
James Larkin,18 John B A G Haanen,19 Leonard H Calabrese   ,20 Xavier Mariette,21,22 
Thierry Schaeverbeke1
To cite: Kostine M, Finckh A, 
Bingham 3rd CO, et al. 
Ann Rheum Dis Epub ahead 
of print: [please include Day 
Month Year]. doi:10.1136/
annrheumdis-2020-217139
Handling editor Josef S 
Smolen
 ► Additional material is 
published online only. To view 
please visit the journal online 
(http:// dx. doi. org/ 10. 1136/ 
annrheumdis- 2020- 217139).
For numbered affiliations see 
end of article.
Correspondence to
Dr Marie Kostine, 
Rheumatology, Centre 
Hospitalier Universitaire de 
Bordeaux Groupe hospitalier 
Pellegrin, Bordeaux 33000, 
France;  
 marie. kostine@ chu- bordeaux. fr
XM and TS are joint senior 
authors.
Received 10 February 2020
Revised 3 April 2020
Accepted 7 April 2020
© Author(s) (or their 
employer(s)) 2020. Re- use 
permitted under CC BY- NC. No 
commercial re- use. See rights 
and permissions. Published 
by BMJ.
AbsTRACT
background Rheumatic and musculoskeletal immune- 
related adverse events (irAEs) are observed in about 
10% of patients with cancer receiving checkpoint 
inhibitors (CPIs). Given the recent emergence of these 
events and the lack of guidance for rheumatologists 
addressing them, a European League Against 
Rheumatism task force was convened to harmonise 
expert opinion regarding their identification and 
management.
Methods First, the group formulated research 
questions for a systematic literature review. Then, 
based on literature and using a consensus procedure, 4 
overarching principles and 10 points to consider were 
developed.
Results The overarching principles defined the role 
of rheumatologists in the management of irAEs, 
highlighting the shared decision- making process 
between patients, oncologists and rheumatologists. 
The points to consider inform rheumatologists on the 
wide spectrum of musculoskeletal irAEs, not fulfilling 
usual classification criteria of rheumatic diseases, 
and their differential diagnoses. Early referral and 
facilitated access to rheumatologist are recommended, 
to document the target organ inflammation. Regarding 
therapeutic, three treatment escalations were defined: 
(1) local/systemic glucocorticoids if symptoms are 
not controlled by symptomatic treatment, then 
tapered to the lowest efficient dose, (2) conventional 
synthetic disease- modifying antirheumatic drugs, in 
case of inadequate response to glucocorticoids or for 
steroid sparing and (3) biological disease- modifying 
antirheumatic drugs, for severe or refractory irAEs. 
A warning has been made on severe myositis, a 
life- threatening situation, requiring high dose of 
glucocorticoids and close monitoring. For patients 
with pre- existing rheumatic disease, baseline 
immunosuppressive regimen should be kept at the 
lowest efficient dose before starting immunotherapies.
Conclusion These statements provide guidance on 
diagnosis and management of rheumatic irAEs and aim 
to support future international collaborations.
InTRoduCTIon
Although the concept of immunotherapy in cancer 
is far from new, monoclonal antibodies targeting 
immunological checkpoints or ‘checkpoint inhibi-
tors’ (CPIs) represent a growing class of agents across 
multiple tumour types and at all stages of disease. 
Agents targeting the T- cell cytotoxic T- lymphocyte- 
associated protein 4 (CTLA-4) or the programmed 
cell death- (ligand) 1 (PD-1/PD- L1) coinhibitory 
receptors marked a turning point in the success of 
immunotherapeutic approaches.1–3 By enhancing 
antitumour T- cell activity, unprecedented long- 
lasting tumour responses were observed in patients 
with unresectable or advanced metastatic disease.4–7 
The clinical value of these immune CPIs, as single 
agents or in combination, is being investigated in 
various solid tumours and haematological malig-
nancies, and their use is expanding rapidly.8 So far, 
the Food and Drug Administration and the Euro-
pean Medicines Agency approved seven immune 
checkpoint- blocking antibodies in selected cancers: 
one anti- CTLA-4 (ipilimumab), three anti- PD-1 
(nivolumab, pembrolizumab and cemiplimab) and 
three anti- PD- L1 (atezolizumab, avelumab and 
durvalumab).
The T- cell activation induced by CPIs commonly 
promotes inflammatory or autoimmune- like side 
effects, known as immune- related adverse events 
(irAEs).9 Compared with conventional cancer ther-
apies, this spectrum of toxicities is unique and can 
affect any organ system, most frequently the skin, 
gastrointestinal tract, endocrine glands and lung. 
Among irAEs, specific rheumatic manifestations 
have been described rather rarely in randomised 
clinical trials, but are much more common in clinical 
practice. The clinical features of rheumatic irAEs 
have been described in a growing number of case 
series and reports.10 However, despite the growing 
interest for irAEs among rheumatologists, evidence 
is lacking for the optimal diagnostic approach and 
the management of these patients in ways that also 
permit effective antitumour therapy to continue. 
According to a recent survey, a large proportion of 
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rheumatologists have limited experience and little confidence in 
managing rheumatic irAEs, highlighting the need for education 
and recommendations in this emerging condition.11
In 2017, the European Society for Medical Oncology devel-
oped clinical guidelines for the management of immune toxic-
ities and mentioned the paucity of literature on management 
of rheumatic irAEs.12 Three other consensus recommenda-
tions have been proposed by the Society for Immunotherapy 
of Cancer, the American Society of Clinical Oncology and The 
National Comprehensive Cancer Network, which among others 
included the management of inflammatory arthritis, polymyalgia 
rheumatica and myositis.13–15 This European League Against 
Rheumatism initiative assembled international experts primarily 
from the rheumatology and immunology but also the oncology 
field with the explicit goal of generating the first set of recom-
mendations for the diagnosis and the management of rheumatic 
irAEs arising as a direct consequence of CPI. Rheumatologists, 
but also in some countries internists and immunologists, have to 
play a pivotal role in developing with the oncologists a patient- 
centred approach to improve the management of rheumatic 
irAEs. While the initiative primarily set out to guide clinicians, 
it is noteworthy that there is limited and rapidly changing litera-
ture and that future additional studies can drastically change the 
profile for diagnosis and management. This area will be a contin-
ually evolving field; therefore, the accompanying comments may 
also serve as a framework for future longitudinal cohorts and/or 
clinical studies.
MeTHods
After approval by the European League Against Rheumatism 
Executive Committee, an international task force was convened 
to develop points to consider for the diagnosis and the manage-
ment of rheumatic irAEs due to cancer immunotherapy. Among 
these members, were 19 clinical experts from Europe and 
North America (14 rheumatologists including 2 delegates of the 
European League Against Rheumatism young rheumatologists’ 
network EMEUNET, 2 internists and 3 oncologists), 1 clinical 
epidemiologist, 1 allied health professional and 2 patient repre-
sentatives from the PARE network of patient research partners. 
The process adhered to the updated European League Against 
Rheumatism standardised operating procedures for the develop-
ment of recommendations.16
In July 2018, the first meeting was convened in Zürich, Swit-
zerland, to define the focus of the task force, identify the target 
population and the research questions for the systematic liter-
ature review (SLR). The SLR was performed by the research 
fellow (MK), with support from the clinical epidemiologist (AF) 
and a librarian (Catherine Weill), to identify relevant publica-
tions through December 2018. Based on the findings of the SLR, 
a first draft of points to consider including 12 items was prepared 
by the fellow (MK) and the two convenors (TS and XM).
SLR results were presented at a second meeting that was held 
in Zürich, Switzerland, in January 2019. Following the evalu-
ation of literature and a group discussion of the first draft of 
propositions, the task force formulated overarching principles 
and consensus statements. Each proposal was then submitted to 
a voting process, requiring at least 75% of votes in the first ballot 
for each recommendation to be accepted. In case this threshold 
was not achieved, further discussion and textual changes were 
proposed for a second round, for which a 67% majority was 
required. Five members of the task force could not attend this 
second meeting, but they subsequently commented and voted 
on each statement by email. The level of evidence (LoE) and 
grade of recommendation was based on the Oxford Levels of 
Evidence.17 After this second face- to- face meeting, members of 
the task force were asked to anonymously rate each item in an 
online survey, on a scale of 0 (absolutely disagree) to 10 (abso-
lutely agree) to assess the level of agreement (LoA). Furthermore, 
the task force agreed on adding relevant references published 
between the SLR and the writing of this manuscript. The manu-
script was reviewed and approved by all task force members and 
the European League Against Rheumatism Executive Committee 
before submission.
ResulTs
systematic literature review
The literature search strategy and summary of results are 
detailed in online supplementary data. The first objective was to 
identify phase III clinical trials to assess the frequency and type 
of rheumatic and musculoskeletal diseases’ (RMDs) complaints 
associated with CPI compared with the comparator group. The 
search was performed using Medline, Embase and the Cochrane 
Library, through December 2018. Among 630 references identi-
fied, 22 studies were selected for inclusion. The second objective 
was to obtain detailed information on rheumatic and musculo-
skeletal symptoms that have been described under CPI treat-
ment. The third objective was to assess outcomes in patients with 
pre- existing autoimmune diseases. Therefore, relevant keywords 
relative to three key domains were used in Medline and Embase 
databases: immune CPIs, rheumatic and systemic diseases and 
adverse events. Abstracts from the last two European League 
Against Rheumatism and American College of Radiology meet-
ings were included, combined with manual searches from refer-
ences of the selected articles. From among 2156 references 
identified, 170 were included, including pharmacovigilance 
registries (n=5), case series (n=51) and case reports (n=114).
After group discussion of the results of the SLR, the 
consensus process was initiated and the full task force agreed 
on a final set of 4 overarching principles and 10 points to 
consider (table 1).
overarching principles
A. Rheumatic and musculoskeletal immune- related adverse events 
can occur as manifestations in cancer patients receiving immuno-
therapy with checkpoint inhibitors (LoE na; LoA 9.6).
Analysis of phase III clinical trials revealed that arthralgia, 
arthritis, myalgia, myositis, dry mouth, musculoskeletal and 
back pain were reported in patients receiving CPI. However, 
their frequency was not significantly different to that of 
patients receiving chemotherapy or placebo.5 18–38 Data from 
several series, both retrospective and prospective, reporting 
prevalences of rheumatic irAEs in real life, ranging from 1.5% 
to 22%, suggest that rheumatic irAEs are under- reported in 
clinical trials.39–54 Of note, an heterogeneous definition of 
rheumatic irAEs may explain such wide interval. Many clin-
ical trials do not report rheumatic irAEs (by disregarding of 
musculoskeletal/rheumatic events as a distinct organ system, 
even in the online supplementary data) or partially only report 
high- grade and/or frequent adverse events (ie, occurring in 
≥10% of the patients). Therefore, the task force wanted to 
emphasise with this first principle that rheumatic and muscu-
loskeletal manifestations are a relevant part of the broad spec-
trum of irAEs.
B. Management of rheumatic and musculoskeletal immune- related 
adverse events should be based on a shared decision- making process 
between patients, oncologists and rheumatologists (LoE na; LoA 9.5).
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Table 1 Overarching principles and points to consider for the diagnosis and management of rheumatic irAEs
loe GoR loA (0–10) mean (sd)
overarching principles
A. Rheumatic and musculoskeletal immune- related adverse events can occur as manifestations in cancer patients 
receiving immunotherapy with checkpoint inhibitors.
n.a. n.a. 9.6 (0.7)
B. Management of rheumatic and musculoskeletal immune- related adverse events should be based on a shared 
decision- making process between patients, oncologists and rheumatologists.
n.a. n.a. 9.5 (1.1)
C. Rheumatologists should engage with oncologists to contribute to the inter- disciplinary care of patients presenting 
with musculoskeletal signs and symptoms.
n.a. n.a. 9.1 (1.2)
D. The role of rheumatologists is to assist oncologists in differential diagnosis and to relieve rheumatic and 
musculoskeletal symptoms to an acceptable level enabling patients to maintain effective cancer immunotherapy.
n.a. n.a. 9.5 (0.9)
Points to consider
1. Rheumatologists should be aware of the wide spectrum of clinical presentations of rheumatic and/or systemic 
immune- related adverse events that often do not fulfil traditional classification criteria of RMDs.
4 C 9.5 (1.2)
2. Oncologists should be encouraged to consult rheumatologists promptly for assessment when rheumatic 
musculoskeletal and systemic signs or symptoms are suspected due to immunotherapy, and rheumatologists should 
provide facilitated access for such patients.
5 D 9.4 (1.3)
3. Metastases, paraneoplastic syndromes and unrelated rheumatic diseases should be considered as a potential 
differential diagnosis of rheumatic immune- related events. The comprehensive assessment should be focused on 
documenting evidence of target organ inflammation, and based on history, clinical features, laboratory tests, imaging 
and/or biopsy.
4 C 9.5 (0.9)
4. In case of inefficacy of symptomatic treatment and depending on the disease severity, local and/or systemic 
glucocorticoids should be considered for immune- related rheumatic and systemic symptoms. Dose regimen and route 
of administration should be decided according to the clinical entity and activity. When improvement is achieved, 
systemic glucocorticoids should be tapered to the lowest effective dose to control the symptoms.
4 C 9.4 (1)
5. csDMARD should be considered in patients with insufficient response to acceptable dose of glucocorticoids or 
requiring glucocorticoid- sparing.
4 C 9 (1.2)
6. For patients experiencing severe immune- related rheumatic and systemic immune- related adverse events or with 
insufficient response to csDMARD, bDMARD may be considered, with TNF or IL-6 inhibitors being the preferred 
options for inflammatory arthritis.
4 C 8.8 (1.2)
7. The decision to hold or to continue the cancer immunotherapy should be based on the severity of rheumatic immune- 
related adverse events, the extent of required immunosuppressive regimen, the tumour response and its duration, as 
well as the future oncology treatment plan, in a shared decision with the patient.
5 D 9.4 (1)
8. Myositis may be a severe condition. Immunotherapy withdrawal needs to be discussed. In the presence of life- 
threatening manifestations (bulbar symptoms (dysphagia, dysarthria, dysphonia), dyspnoea and myocarditis), high 
dose of glucocorticoids, IVIg and/or plasma exchange should be considered; immunotherapy withdrawal is always 
necessary.
4 C 8.9 (1.2)
9. A pre- existing autoimmune rheumatic and/or systemic disease should not preclude the use of cancer immunotherapy. 
Baseline immunosuppressive regimen should be kept at the lowest dose possible (for glucocorticoids, below 10 mg 
prednisone per day if possible). However, many patients may have a flare of the underlying condition and/or immune- 
related adverse events, requiring the use of glucocorticoids and/or DMARDs.
4 C 9 (1.3)
10. Before initiation of cancer immunotherapy, there is no indication to test every patient for the presence of 
autoantibodies. In the case of unexplained rheumatic, musculoskeletal or systemic symptoms, a complete 
rheumatological assessment should be performed.
5 D 9 (1.3)
GoR: A: based on consistent level 1 studies; B: based on consistent level 2 or 3 studies or extrapolations from level 1 studies; C: based on level 4 studies or extrapolations from 
level 2 or 3 studies; D: based on level 5 studies or on troublingly inconsistent or inconclusive studies of any level.
LoE: 1a: systematic review of RCTs; 1b: individual RCT; 2a: systematic review of cohort studies; 2b: individual cohort study (including low- quality RCT); 3a: systematic review of 
case–control studies; 3b: individual case–control study; 4: case- series (and poor quality cohort and case–control studies); 5: expert opinion without explicit critical appraisal, or 
based on physiology, bench research or ‘first principles’.
bDMARD, biological disease- modifying antirheumatic drug; csDMARD, conventional synthetic disease- modifying antirheumatic drug; DMARD, disease- modifying antirheumatic 
drug; GoR, grade of recommendation; IL-6, interleukin 6; irAEs, immune- related adverse events; IVIg, intravenous immunoglobulin; LoA, level of agreement; LoE, level of 
evidence; RCT, randomised clinical trial; RMD, rheumatic and musculoskeletal disease; TNF, tumour necrosis factor.
Rheumatic and musculoskeletal irAEs occur in a context 
of cancer; therefore, a dialogue between rheumatologists 
and oncologists is important to balance the harm and risk of 
oncology treatment and immunosuppressive drugs. The most 
important stakeholder is the patient. Shared decision between 
a patient and his/her rheumatologist is a fundamental principle 
of RMDs management, as illustrated by its representation as an 
overarching principle in several European League Against Rheu-
matism recommendations.55–57 Because evidence- based data 
for irAEs management are limited, and irAEs can have a large 
impact on the quality of life, patient’s preferences and discus-
sions concerning risks and benefits of each treatment option are 
even more important.
C. Rheumatologists should engage with oncologists to contribute 
to the inter- disciplinary care of patients presenting with musculo-
skeletal signs and symptoms (LoE na; LoA 9.1).
IrAEs may affect any organ system including the rheumatic 
and musculoskeletal system. Some patients may even experi-
ence multiple organ toxicities in sequence or concurrently. The 
importance of developing a local multidisciplinary network 
of oncologists and specialists of all organ system potentially 
involved in the management of irAEs has been recently high-
lighted.58 59 Rheumatologists should actively engage in these 
local multidisciplinary networks as valuable members due 
to their knowledge of clinical immunology, their expertise 
in multiorgan autoimmune disease and their long- standing 
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experience with the use of immunosuppressive drugs and 
biological therapies.60 This engagement should also include 
efforts aimed at improving patient education before or when 
starting cancer immunotherapy, to prevent delay in diag-
nosis when rheumatic or musculoskeletal side effects occur. 
Patients have reported that they were informed about other 
immune- related side effects more than rheumatic or muscu-
loskeletal symptoms.61 Furthermore, since the rheumatic and 
the cancer disease both induce high impact on the patient’s 
life, even when independently considered and when disease 
activity is controlled (ie, fatigue, pain, functional impairments, 
emotional problems, secondary effects of the treatments), the 
value of an interdisciplinary collaboration between the rheu-
matologist and the oncologist is worthwhile.
D. The role of rheumatologists is to assist oncologists in estab-
lishing the diagnosis and to relieve rheumatic and musculoskele-
tal symptoms to an acceptable level enabling patients to maintain 
effective cancer immunotherapy (LoE na; LoA 9.5).
This principle aimed to better define the role of rheumatol-
ogists as oncologists’ partners based on the clinical experience 
of the task force members. Once a patient with cancer receiving 
immunotherapy is referred for evaluation of rheumatic or 
musculoskeletal symptoms, the rheumatologist should consider 
several potential aetiologies: tumour progression, paraneoplastic 
syndromes, non- rheumatic events (ie, viral infection, thrombosis, 
endocrine abnormality), all already considered by the referring 
oncologist, or rheumatic/systemic irAE or immune non- related 
adverse events. This aspect of differential diagnosis is also 
described in more detail in recommendation 3. Once a rheu-
matic irAE is diagnosed, the supervising rheumatologist should 
propose an appropriate treatment to relieve patient’s symptoms 
to an acceptable level with the objective of maintaining quality 
of life and permitting continuation of effective cancer immuno-
therapy, if this is recommended by the oncologist. This treatment 
goal is different to classic rheumatic entities, in which usually 
remission is the targeted treatment outcome.
Points to consider
1. Rheumatologists should be aware of the wide spectrum of clini-
cal presentations of rheumatic and/or systemic immune- related ad-
verse events that often do not fulfil traditional classification criteria 
of RMDs (LoE 4; LoA 9.5).
While arthralgia and myalgia were the most commonly 
reported rheumatic irAEs in clinical trials, numerous case series 
and reports have captured a broader spectrum of de novo rheu-
matic and systemic manifestations that can occur with cancer 
immunotherapy.62–64 Polymyalgia rheumatica (PMR)- like 
syndromes and inflammatory arthritis syndromes are two of the 
major clinical presentations encountered.39–41 48 65 66 PMR- like 
manifestation occurred with a median exposure time to CPI of 
60 days, but also much later (IQR 24–210 days). Exposure time 
to CPI was generally longer for patients experiencing inflamma-
tory arthritis (median 120 days, IQR 48–262 days). In addition, a 
variety of other rheumatic syndromes have been reported. These 
include arthralgia; monoarthritis, oligoarthritis or polyarthritis; 
reactive arthritis; psoriatic arthritis (PsA); remitting seronegative 
symmetrical synovitis with pitting oedema (RS3PE); tenosyno-
vitis; enthesitis; non- inflammatory musculoskeletal conditions 
and osteoarthritis.41 44 46 51 66–77 Importantly, autoantibodies 
are often absent. In arthritis, only a few patients are positive 
for rheumatoid factor (RF; n=20, range 18–246 UI/mL) and/
or anti- citrullinated peptide antibodies (ACPAs; n=14, range 
18–614 U/mL).78 Instead, positivity of antinuclear antibodies 
(ANAs) is observed, but often at a low titre (range 1:80 to 
1:3200, one patient with ANA 1:12 800 and only 35 patients 
with ANA >1:160). Similarly, acute phase reactants may be 
normal in some patients with PMR- like presentations.41 Overall, 
around 20% of patients fulfilled classification criteria of rheu-
matoid arthritis (RA) (55/271) or PMR (11/52). This percentage 
was higher (55%) for PsA (6/11), as well as in a recent series 
of PMR- like syndrome (37/49; 75%).79 The first observation of 
recurrent pseudogout flares 7 to 10 days after each nivolumab 
infusion has been recently reported.80
Several cases of myositis have been reported, with frequent 
limb- girdle myalgia and weakness that may mimic a PMR- like 
condition.81–83 Because it represents a potentially life- threatening 
complication, the task force decided to formulate a dedicated 
recommendation on myositis (recommendation 8).
Among systemic manifestations, sicca syndrome has been 
described early on, presenting mainly with dry mouth, 
and possible associated neurological symptoms in a few 
patients.40 48 65 66 84–87 Two major studies on CPI- induced sicca 
syndrome were published in 2019 and therefore included in this 
manuscript. The ImmunoCancer International Registry reported 
on 26 patients experiencing CPI- associated sicca syndrome. 
This mainly included men, with frequent organ- specific auto-
immune manifestations but lower prevalence of autoantibodies 
(52% ANA, 20% Ro/SS- A, 9% RF, 8% La/SS- B) in comparison 
with classical Sjögren’s syndrome.88 Interestingly, a predominant 
T- cell infiltrate with acinar destruction has been reported in sali-
vary glands, distinct from the histological profile of idiopathic 
primary Sjögren’s syndrome. Authors hypothesise that CPI 
therapy may break immune tolerance locally leading to the acti-
vation of cytotoxic T cells damaging the salivary epithelium.89
Other systemic manifestations have been described, including 
sarcoidosis or sarcoid- like reactions.90–93 The diagnosis is usually 
suspected through imaging when new hilar lymphadenop-
athy or pulmonary nodules are detected in imaging, requiring 
biopsy. Half of patients experienced cutaneous manifestations 
(nodules, rash), and some patients had cough/dyspnoea (29%) 
and arthralgia/arthritis (18%). Uveitis, parotitis, hypercalcaemia 
and neurological symptoms are rarely reported. Some patients 
experienced systemic sclerosis or scleroderma- like reactions, all 
presenting with skin thickening, but only one with new- onset 
Raynaud’s phenomenon.48 94–96 None tested positive for specific 
autoantibodies. Since PD-1- deficient mice spontaneously devel-
oped lupus- like autoimmune diseases with arthritis and glomer-
ulonephritis, such clinical phenotypes could be expected in 
patients treated with anti PD- (L)1 agents, but are not observed. 
A few cases of lupus- like cutaneous reaction and one Jaccoud 
arthropathy have yet been reported with anti- PD-1 agents, and 
only one lupus- like nephritis was attributed to anti- CTLA-4 
treatment.97–102
All vessel- sized vasculitis (eg, large, medium and small vessels) 
with various clinical manifestations, including purpura, digital 
necrosis arthralgia, arthritis, myalgia, fever, fatigue and abdom-
inal pain have also been reported.40 48 84 103–113 Of note, ANA, 
antineutrophil cytoplasmic antibodies (ANCAs), cryoglobulin 
and RF were rarely positive. Analysis of the WHO pharma-
covigilance database revealed that temporal arteritis (n=16) was 
particularly over- reported with ipilimumab monotherapy treat-
ment.114 The first case of granulomatosis with polyangiitis with 
a high anti- PR3 ANCA titre was reported in 2019.115
Recently, patients experiencing rapid bone loss with CPI 
leading to multiple fractures were reported, raising the ques-
tion of a potential influence of immune activation on bone 
metabolism.116
 o
n
 April 30, 2020 by guest. Protected by copyright.
http://ard.bmj.com/
Ann R
heum
 D
is: first published as 10.1136/annrheum
dis-2020-217139 on 23 April 2020. Downloaded from
 
5Kostine M, et al. Ann Rheum Dis 2020;0:1–13. doi:10.1136/annrheumdis-2020-217139
Recommendation
Importantly, rheumatic and/or systemic irAEs may occur across 
all classes of CPI, most frequently and severely with combina-
tion treatments and may be associated with other organ- specific 
irAEs.
2. Oncologists should be encouraged to consult rheumatologists 
promptly for assessment when rheumatic musculoskeletal and sys-
temic signs or symptoms are suspected due to immunotherapy, and 
rheumatologists should provide facilitated access for such patients 
(LoE 5; LoA 9.4).
The data that are available regarding the process of referral 
to a rheumatologist suggests that this is not widely done and 
might lead to delay in diagnosis. In one series, only 4 out of 12 
patients experiencing rheumatic irAEs were reviewed by rheu-
matologists.43 One cohort reported an average of 9.5±9.3 days 
between the counselling request and the first rheumatologist visit 
and 2.5±4.4 months from the start of arthralgias to the confir-
mation of synovitis.67 Two other series reported a median of 34 
days (range 16–210 days) and 7 days (range 1–57 days) before a 
rheumatology appointment.66 117 Rheumatic side effects of CPI 
appear underappreciated, which probably delays proper assess-
ment and treatment. However, as mentioned in the overarching 
principles, a prompt rheumatological evaluation should support 
rapid shared treatment decision to relieve patient symptoms, 
maintain a good quality of life and allow pursuing an effective 
cancer immunotherapy.
Currently, algorithms for irAEs management are based on 
the severity/grade of the irAE according to the Common Termi-
nology Criteria for Adverse Events (CTCAE v5.0). The first inter-
national guidelines recommended referral to a rheumatologist in 
the case of severe symptoms not responding to glucocorticoids 
(grade 3). Subsequently, prompt referral was proposed as soon 
as the patient experienced moderate pain associated with signs 
of inflammation (grade 2).12–14 While CTCAE grading is routine 
for oncologists, and a requirement for clinical trials, rheumatol-
ogists are less familiar with this grading which do not accurately 
reflect the spectrum or severity of rheumatic or systemic mani-
festations (online supplementary table S1). Accordingly, the task 
force decided not to use the CTCAE grading system to prioritise 
referral but instead to recommend prompt assessment, ideally 
before starting glucocorticoids. For this purpose, rheumatolo-
gists should be encouraged to offer facilitated access since they 
may be able to avoid systemic glucocorticoids or use lower dose 
than oncologists to manage rheumatic toxicities.
3. Metastases, paraneoplastic syndromes and unrelated rheumatic 
diseases should be considered as a potential differential diagnosis of 
rheumatic immune- related events. The comprehensive assessment 
should be focused on documenting evidence of target organ inflam-
mation, and based on history, clinical features, laboratory tests, im-
aging and/or biopsy (LoE 4; LoA 9.5).
The first part of this statement has previously highlighted the 
overarching principle of defining the role of the rheumatolo-
gist (overarching principle D). While delaying the diagnosis of 
irAEs and its adequate treatment may result in a worse prognosis 
regarding both CPI adherence and immune- mediated tissue/
organ destruction, focusing only on irAEs without considering 
other differential diagnoses may also be inappropriate. CPIs are 
commonly administered to patients with advanced cancer, and 
so new rheumatic/musculoskeletal symptoms must raise suspi-
cion of cancer progression, as well as the lack of improvement 
of inflammatory arthritis with glucocorticoids (ie, possibility 
of metastases or paraneoplastic syndrome).118 119 Advanced 
imaging, such as CT scan, MRI, bone scintigraphy or positron 
emission tomography- CT, may be helpful in arriving at such a 
diagnosis. The diagnosis of irAEs versus metastasis may become 
even more challenging as non- malignant resorptive lesions have 
recently been described, which can mimic metastases.116 Pulmo-
nary sarcoidosis- like lesions may also be first considered as 
tumour progression.
Immunological toxicities may also manifest as paraneoplastic 
syndromes. Current literature covers mainly paraneoplastic 
neurological syndromes with few published data regarding para-
neoplastic rheumatic syndromes.120 121 However, based on the 
clinical experience of task force members, the group agreed to 
include paraneoplastic syndromes in the differential diagnosis of 
rheumatic irAEs to inform clinicians that they may encounter 
newly and not pre- existing paraneoplastic syndromes following 
CPI therapy, notably hypertrophic osteoarthropathy. RS3PE and 
dermatomyositis were also reported, either as paraneoplastic 
syndromes or induced by CPI therapy, but one may not be able 
to make the distinction when appearing under CPI therapy.
The term ‘unrelated rheumatic diseases’ covers manifestations 
for which the causal link with cancer immunotherapy is not 
obvious, such as shoulder tendinitis, lateral epicondylitis, non- 
inflammatory back pain or complex regional pain syndrome. 
The task force agrees that it may be difficult to establish when a 
specific rheumatic feature can be considered related or unrelated 
to the administration of CPI. Using the adverse drug reaction 
probability score (Naranjo scale) may help to assess the causal 
link with CPI therapy.
The task force proposes that the key objective of the diag-
nostic work- up is to document evidence of target organ inflam-
mation. By adopting the term target organ inflammation, the 
task force wants to emphasise that priority for the supervising 
rheumatologist is not only to search for joint inflammation but 
also to document evidence of any organ inflammation according 
to the symptoms presented (muscle, fascia, vessels, heart, lung, 
skin, endocrine glands, salivary glands, etc), either clinically or 
preferably by using appropriate laboratory tests, imaging and 
tissue biopsy.
Tissue diagnosis should be decided on a case- by- case basis, 
based on the type and severity of rheumatic irAE, when other 
supportive information would not be sufficient to make a clinical 
decision in terms of therapy. Notably, histopathological data may 
be frequently indicated in patients presenting with vasculitis, 
sarcoidosis and myositis, but should not interfere with starting 
treatment, particularly with myositis or patients presenting with 
life- threatening irAE. On the other hand, synovial biopsies will 
not change the acute management of inflammatory arthritis. 
They may provide insights into targeted therapies with gluco-
corticoid saving approaches, but are not recommended for daily 
practice.
4. In case of inefficacy of symptomatic treatment and depending 
on the disease severity, local and/or systemic glucocorticoids should 
be considered for immune- related rheumatic and systemic symp-
toms. Dose regimen and route of administration should be decided 
according to the clinical entity and activity. When improvement is 
achieved, systemic glucocorticoids should be tapered to the lowest 
effective dose to control the symptoms (LoE 4; LoA 9.4).
In the absence of contraindications, symptomatic treatment 
including non- steroidal anti- inflammatory drugs and/or anal-
gesics should be the initial treatment for mild- to- moderate 
rheumatic manifestations. There are no data on the efficacy of 
symptomatic therapies in the context of systemic manifestations. 
An anti- inflammatory effect of these drugs can be expected within 
several hours or a few days. Additionally, intra- articular gluco-
corticoids should be considered in the context of monoarthritis 
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or oligoarthritis, combined with an analysis of the synovial 
fluid, whenever possible, to rule out differential diagnoses such 
as infection, osteoarthritis or crystals.40–42 48 66 67 75–77 122–126 If 
symptomatic treatment is insufficient and tissue inflammation 
is still evident, systemic glucocorticoids should be considered 
for both immune- related rheumatic and systemic symptoms. 
Overall, systemic glucocorticoids were used for 224/296 patients 
(76%) with arthritis39–44 46 48 51 52 65–74 76–78 83 116 122 123 125–143 with 
a median dosage of 20 mg/day, for 37/65 patients (57%) with 
sicca syndrome39 40 65 66 85–89 with a median dosage of 40 mg/day 
(16 patients for sicca symptoms, 15 patients for systemic mani-
festations or associated arthritis, 6 patients for sicca symptoms 
and associated other irAE), for 22/29 patients (76%) with vascu-
litis48 84 103–106 108–112 144–150 with a median initial dosage of 60 
mg/day, for 15/33 patients (45%) with sarcoidosis39 44 91–93 151–158 
with a median initial dosage of 55 mg/day, for 7/7 patients 
(100%) with scleroderma48 94–96 with an initial dosage of 1 mg/
kg/day and for 4/13 patients (31%) with lupus.98–101 Subacute 
cutaneous lupus was mainly treated with topical steroids.97 
Treatment of patients with myositis is reported in a separate 
statement (point to consider 8).
So far, there are reassuring data regarding the use of glucocor-
ticoids for irAE management.159 160 For rheumatic irAEs, patients 
receiving glucocorticoids equivalent to 10 mg/day of predniso-
lone for 6 weeks concurrent to anti- PD1 therapy had a similar 
antitumour response.77 However, recent preclinical data point 
out that glucocorticoids markedly impair the activation and the 
killing ability of tumour- infiltrating lymphocytes.161 Because of 
concerns of glucocorticoids on antitumour responses, the task 
force did not recommend using methylprednisolone pulses or 
high- dose oral glucocorticoids in the absence of life- threatening 
complications and myositis, even in severe presentations, and 
favoured the concept of glucocorticoid sparing where rheuma-
tologists have extensive experience with alternative options. 
Furthermore, the task force members recommended tapering 
glucocorticoids to the lowest effective dose within weeks or as 
soon as improvement is achieved was desirable. The objective 
of reaching a dose less than or equal to 10 mg/day of equivalent 
prednisone was considered as an acceptable target dose. This 
target dose as maintenance therapy is based on current preclin-
ical and retrospective clinical data,161–163 and higher than the one 
recommended for the main classical RMDs (online supplemen-
tary table S2).
5. csDMARD should be considered in patients with insuffi-
cient response to acceptable dose of glucocorticoids or requiring 
glucocorticoid- sparing (LoE 4; LoA 9).
In case of active rheumatic irAE requiring dose of gluco-
corticoids higher than 10 mg/day of equivalent prednisone, 
conventional synthetic disease- modifying antirheumatic drug 
(csDMARD) should be considered. Several csDMARDs have 
been used as second- line therapy in the case of an insufficient 
response to glucocorticoids or for use as steroid sparing agents. 
So far, no specific biological disease- modifying antirheumatic 
drug has proven superiority. For the various types of arthritis 
in cases reported, methotrexate was the most frequently drug 
prescribed, followed by hydroxychloroquine then sulfasalazine, 
either as monotherapy or in combination.39–41 43 44 48 51 52 65–67 
69 70 75–78 122 123 125 128 131 132 134 140–142 164 165 Of note, no safety 
issues were described regarding long- term use of methotrexate 
associated with CPI in a few patients, with a median follow- up 
of over 1 year.67 It is noteworthy that a higher proportion of 
hypersensitivity reactions were reported with sulfasalazine in 
the context of CPI- induced inflammatory arthritis, suggesting 
caution to its use in those situations.165 One case series reported 
the initiation of hydroxychloroquine prior to glucocorticoids, 
limiting glucocorticoid exposure, which would deserve further 
evaluation.166 The use of csDMARDs has not been described 
for patients with CPI- induced sicca syndrome. Two patients 
received hydroxychloroquine and one the combination of 
hydroxychloroquine and methotrexate for cutaneous leuco-
cytoclastic vasculitis.103 One patient with granulomatosis with 
polyangiitis was treated with oral cyclophosphamide.105 For 
other systemic manifestations, hydroxychloroquine was safely 
prescribed for patients with CPI- induced lupus and scleroderma 
and in one patient with sarcoidosis.48 95–100 157 Four patients 
with scleroderma- like syndromes received mycophenolate 
mofetil.48 94 96 Among them, two also received intravenous 
immunoglobulin. Finally, two patients with neurosarcoidosis 
were successfully treated with methotrexate after an infusion 
reaction to infliximab.92 93
6. For patients experiencing severe rheumatic and systemic immune- 
related adverse events or with insufficient response to csDMARD, 
bDMARD may be considered, with TNF or IL-6 inhibitors being 
the preferred options for inflammatory arthritis (LoE 4; LoA 8.8).
Gastroenterologists have safely and successfully administered 
infliximab for patients with severe CPI- induced colitis who 
had an insufficient response to glucocorticoids.167 168 Based on 
these data, tumour necrosis factor (TNF) inhibitors (infliximab 
prevailing on etanercept and adalimumab) have been reported 
for severe and refractory inflammatory arthritis.65 66 116 123 138 
However, while patients experiencing colitis required one or two 
infliximab infusions, patients with arthritis may require long- 
term administration of TNF inhibitors, which is an important 
difference of unclear clinical significance at this time. A recent 
study reported that antitumour responses were not adversely 
affected in patients treated with TNF inhibitors, with a median 
follow- up of 9 months, but further data are needed.169 Preclin-
ical data support the use of TNF inhibitors, since infliximab only 
had a minor influence on T- cell activation and the killing ability 
of tumour- infiltrating lymphocytes, whereas even low doses of 
glucocorticoids markedly impaired this antitumour activity.161 
Furthermore, a synergistic effect of TNF inhibitors with CPI has 
been demonstrated in mouse models.170 171 A phase I investigator- 
initiated trial (TICIMEL, NCT03293784) is currently testing the 
safety of this combined approach (double immunotherapy plus 
TNF inhibitor) in patients with melanoma. Results of this study 
will likely inform the management of rheumatic irAEs. The use 
of infliximab was also reported in two patients with neurosar-
coidosis.92 93
There are also several observations in patients with CPI- 
induced inflammatory arthritis treated with tocilizumab.48 52 68 83 
Notably, one patient responded to tocilizumab after infliximab 
failure.52
Regarding interleukin 17 blockade, the use of secukinumab 
has been reported in a patient with mismatch- repair- deficient 
metastatic colon cancer and a previous history of Crohn’s disease 
who experienced colitis, severe psoriatic rash and arthralgia.172 
While providing a dramatic relief of the immune- related skin, 
rheumatic and gastrointestinal side effects, subsequent tumour 
progression was observed. A second recent publication described 
the complete resolution of pembrolizumab- induced psoriasiform 
eruption with secukinumab in a patient with melanoma, without 
impact on tumour response.173 Due to limited data and concerns 
about interleukin 17 inhibition on CPI efficacy, the task force 
agreed not to recommend interleukin 17 blockade for inflam-
matory arthritis.
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For mechanistic reasons, abatacept should also not be consid-
ered for the treatment of CPI- induced rheumatic and systemic 
diseases, owing to the hypothetical risk of antagonising antitu-
mour responses of CPI. However, one may consider its use in 
cases of life- threatening conditions, as discussed in the statement 
for myositis (point to consider 8).
One patient with neuro- Sjögren’s syndrome was success-
fully treated with rituximab after intravenous pulses of 
methylprednisolone, immunoglobulins and one dose of cyclo-
phosphamide.87 Rituximab was also used in one patient with 
acral vasculitis without improvement and the need of surgical 
amputation.105
7. The decision to hold or to continue the cancer immunotherapy 
should be based on the severity of rheumatic immune- related adverse 
events, the extent of required immunosuppressive regimen, the tu-
mour response and its duration, as well as the future oncology treat-
ment plan, in a shared decision with the patient (LoE 5; LoA 9.4).
Currently, decisions regarding CPI and immunosuppres-
sive regimens vary from institution to institution according to 
local practice, with no randomised trials to provide evidence in 
choosing between holding CPI and/or introducing an immuno-
suppressive regimen. Overall, the SLR revealed that CPIs were 
discontinued in 25% of patients experiencing inflammatory 
arthritis, 61% of patients with sicca syndrome (a discontinuation 
of CPI often due to another associated irAE), 80% of patients 
with vasculitis, 64% of patients with sarcoidosis, 75% of patients 
with scleroderma and 78% of patients with lupus. It is note-
worthy that several studies reported ongoing clinical benefit 
in patients who discontinue their cancer immunotherapy for 
irAEs.7 174 175 Well- designed prospective trials will be required 
help to clarify the optimal immunosuppressive regimens.
8. Myositis may be a severe condition. Immunotherapy withdrawal 
needs to be discussed. In the presence of life- threatening manifes-
tations (bulbar symptoms (dysphagia, dysarthria, dysphonia), dys-
pnoea and myocarditis), high dose of glucocorticoids, IVIg and/or 
plasma exchange should be considered; immunotherapy withdraw-
al is always necessary (LoE 4; LoA 8.9).
Myositis belongs to the spectrum of potentially fatal toxicity 
associated with CPI, since it is frequently associated with myocar-
ditis and/or myasthenia gravis.176–178 Notably, it generally occurs 
very early after CPI initiation, often within the first month 
of treatment (median exposure time of 25 days, IQR 25–45 
days). Proximal weakness and myalgia are the major symptoms, 
which can mimic a PMR- like condition.81 Therefore, a high 
awareness for myositis is needed among rheumatologists with 
measurement of creatine kinase (CK) since increased CKs are 
seen in the majority of patients with myositis (median of 2650 
IU/L, ranging from 335 to 20 270 IU/L).48 77 81–83 100 117 179–207 
Of note, CK levels are usually within the normal range in 
patients presenting with myalgia.42 83 Ptosis and diplopia are also 
commonly reported and may be related to associated myasthenia 
gravis.81 82 100 117 184 185 189 191 192 195 197 198 204 205 208–210 Of note, 
some patients present with dropped head syndrome.82 198 211 
Importantly, one should search for the presence of life- threatening 
manifestations, including dyspnoea, palpitations, chest pain or 
syncope, which should alert on a possible concurrent myocar-
ditis.39 48 77 81–83 117 177–179 182 184 185 187 190 193 200 207 211–215 Of 
note, an increased risk of death in patients experiencing CPI- 
related myositis has been observed compared with patients with 
idiopathic inflammatory myositis (around 20% vs less than 
10%).177 216 This increased mortality rate seems to be related 
to the development of myocarditis. While there is no stan-
dardised assessment of myocarditis in large series of idiopathic 
inflammatory myopathy, signs of myocardial inflammation 
cardiac has been reported on magnetic resonance tomog-
raphy in more than 60% of such patients,217 which argue that 
myocarditis belong to the myositis clinical spectrum and does 
not represent a different concomitant irAE. Therefore, cardiac 
evaluation must be systematic for any patient with myositis 
or suspected myositis. It includes cardiac troponin (troponin 
T is less specific than troponin I in case of associated skeletal 
muscle diseases) and electrocardiography. In case of clinical 
syndrome associated with myocarditis and/or increase cardiac 
troponin level and/or electrocardiography, a cardiac MRI is 
necessary.218 Of note, normal cardiac enzyme cannot always rule 
out the possibility of myocarditis. Furthermore, the presence 
of bulbar symptoms (dysphagia, dysarthria, dysphonia) and/
or respiratory failure may be related to myositis or associated 
myasthenia gravis encountered in 12.5% of patients (57/454 
cases reported).82 83 100 177 178 186 188 189 192 195 203 204 208 211 212 Of 
note, the majority of patients will not have a typical skin rash of 
dermatomyositis, only reported in a few patients.199 201 219
Myositis- associated autoantibodies are mostly negative, 
though cases with positive ANA, antistriated antibodies, anti- PM/
Scl, anti- SM, anti-TIF1 gamma, anti- PL-7, anti- PL12, anti- Jo1 or 
anti- SRP have been reported.77 83 117 184 Electrodiagnostic studies 
usually reveal myopathic pattern with musculature enhance-
ment may be observed on MRI. Biopsy is often performed and 
confirms muscle damage with variable degrees of inflammatory 
and necrotic changes.81 Of interest, fasciitis is also increasingly 
reported clinically and seen on MRI findings.40 76 220–224
Prompt recognition and early management of myositis is 
imperative. Discontinuation or at least interruption of CPI 
was reported in more than 85% of patients and is manda-
tory in the presence of dyspnoea, bulbar symptoms, severe 
muscle weakness and/or myocarditis. High- dose systemic 
glucocorticoids are the first- line treatment, usually 1–2 mg/
kg/day (median dosage 70 mg/day). Ten per cent of reported 
patients received intravenous pulses of methylprednisolone. 
Up to 20% of patients also received intravenous immunoglob-
ulins,39 48 77 81–83 181 183–185 188 189 191 198 201 207–209 211 212 220 225 226 
and plasma exchanges were performed in around 10% of 
patients.48 81 82 117 150 184 188 189 191 197 204 205 226 As second- line 
therapy, several csDMARDs have been used: mycopheno-
late mofetil,77 209 225 methotrexate,39 44 77 81 azathioprine in 
one patient but stopped for pancreatitis77 and hydroxychlo-
roquine in one patient.76 Six patients have been treated with 
infliximab, but only one successfully.82 182 184 225 Importantly, 
a recent publication reported the resolution of a severe 
glucocorticoid- refractory myocarditis with abatacept, received 
after plasma exchanges was unsuccessful.227 Another T- cell 
directed therapy, alemtuzumab, has been successfully used in 
a patient with glucocorticoid- refractory myocarditis.228 The 
task force agreed that further evaluation is warranted, most 
notably on the impact on tumour response; however, due to 
the lack of effective therapy and the high mortality rate of 
myositis complicated with myocarditis or severe respiratory 
failure, one may consider their use as rescue therapy in refrac-
tory situations.
9. A pre- existing autoimmune rheumatic and/or systemic disease 
should not preclude the use of cancer immunotherapy. Baseline 
immunosuppressive regimen should be kept at the lowest dose pos-
sible (for glucocorticoids, below 10 mg prednisone per day if pos-
sible). However, many patients may have a flare of the underlying 
condition and/or immune- related adverse events, requiring the use 
of glucocorticoids and/or DMARDs (LoE 4; LoA 9).
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Patients with pre- existing inflammatory or autoimmune 
disease have been largely excluded from clinical trials due to 
the theoretical risk of worsening autoimmune manifestations. 
However, there are several series reporting on CPI safety in such 
patients, with either anti- CTLA-4229–231 or anti- PD- (L)1 .77 232–235 
Together, a flare of the pre- existing inflammatory or autoim-
mune disease was observed in half of patients with RA (47/86 
patients), PsA (4/8 patients) and myositis (1/2 patients), 64% of 
patients with PMR (16/25 patients), 31% of patients with SA 
(4/13 patients) and patients with systemic lupus erythematosus 
(4/13 patients), 43% of patients with Sjögren’s syndrome (3/7 
patients), 25% of patients with systemic sclerosis (2/8 patients) 
and 20% of patients with sarcoidosis (3/15 patients), but less 
than 10% had to stop CPI therapy during a flare. The patient 
with pre- existing giant cell arteritis experienced a relapse. There 
was no flare reported for the few patients with pre- existing 
seronegative arthritis (n=4), other vasculitis (n=4) and Behçet’s 
disease (n=1). Furthermore, 18 of 104 patients (17%) experi-
enced other irAEs, mainly colitis (n=12), hypophysitis (n=3) 
and thyroiditis (n=3). One patient with RA developed myositis 
requiring high dose of glucocorticoids and intravenous immu-
noglobulins, and another patient with RA developed Sjögren’s 
syndrome with autoantibodies (ANA 1/1280, anti- SSA and 
SSB). Overall, CPI was discontinued in 8% of patients with pre- 
existing autoimmune disease due to other irAEs, unrelated to 
their pre- existing autoimmune disease. In a recent case series 
of 112 patients with pre- existing autoimmune diseases treated 
with CPI, a flare of pre- existing autoimmune disease or another 
irAE occurred in 71% of the patients (47% has a flare of their 
pre- existing disease and 43% had another irAE).236 Thus, the 
occurrence of a flare/irAE was frequent but mostly manageable 
without CPI discontinuation in 79% of the patients.
In these case series, most flares and irAEs were managed with 
glucocorticoids, with the need of csDMARDs in some patients, 
usually hydroxychloroquine, methotrexate, sulfasalazine, either 
in monotherapy or in combination. The need for TNF inhibitors 
was only reported in patients with flares of their inflammatory 
bowel disease flares and in two cases of new- onset colitis. Based 
on these data, the task force agreed that CPI therapy in patients 
with pre- existing autoimmune rheumatic and systemic disease was 
not contraindicated, provided that the patient is well- informed and 
closely monitored. No preventive treatment is needed. Importantly, 
this remains a shared decision between the oncologist, rheumatolo-
gist and the patient, and whether CPI will be used in a metastatic or 
adjuvant setting is a major aspect to be considered.
Regarding baseline immunosuppressive regimen, recent preclin-
ical and clinical data highlighted the deleterious impact of baseline 
glucocorticoids on CPI efficacy, when used at a dosage of greater 
than 10 mg/day.163 237 However, this was in patients treated with 
steroids for their cancer or cancer- related symptoms and not for 
autoimmune symptoms. Accordingly, the task force agreed on 
recommending the lowest immunosuppressive regimen possible 
at the start of CPI therapy. However, future data on prophylactic 
TNF inhibition and a possible synergistic effect of TNF inhibitors 
and CPI, reported in a mouse model and currently evaluated in 
patients, may challenge this statement over time.171
10. Before initiation of cancer immunotherapy, there is no indica-
tion to test every patient for the presence of autoantibodies. In the 
case of unexplained rheumatic, musculoskeletal or systemic symp-
toms, a complete rheumatologic assessment should be performed 
(LoE 5; LoA 9).
Analysis of pretreatment and post- treatment sera of anti- 
CTLA4- treated patients with melanoma revealed that for 
most autoantibodies, including RA- associated antibodies, post- 
treatment titres increased only marginally and were not asso-
ciated with the occurrence of irAEs.238 Similarly, the presence 
of ANA in serum collected prior to initiating CPI therapy 
was not found to predict the development of irAEs, except 
for colitis.239 240 One study reported divergent data, with pre- 
existing antibodies independently associated with the occurrence 
of irAEs, but also with clinical benefits on advanced non- small 
cell lung cancer.241 Notably, skin reactions were more frequent 
among patients with pre- existing RF.
Since autoantibodies are not found in the majority of patients 
experiencing CPI- induced rheumatic and systemic disease, there is 
no indication to test every patient at baseline. Of note, the presence 
of ACPAs has been detected in serum samples obtained prior to 
CPI therapy in few patients who experienced RA and were asymp-
tomatic before the start of CPI.78 But this situation might be rare, 
and the detection of autoantibodies in an asymptomatic patient 
would not preclude the start of CPI therapy. However, there is the 
particular situation of patients with thymoma who develop CPI- 
induced myositis and who all have anti- acetylcholine receptor and 
antistriated muscle antibodies detected in serum sample obtained 
prior to CPI therapy.179 Accordingly, as myositis may evolve into 
a severe irAE, testing for the presence of these antibodies before 
starting CPI in a patient with thymoma is recommended to identify 
a high risk of myositis.
ConClusIon
These points to consider provide the basis of an European 
League Against Rheumatism consensus on the diagnosis and the 
management of rheumatic and systemic irAEs which represent a 
new and rapidly expanding field. The task force aimed to raise 
awareness and to assist rheumatologists to improve the diagnosis 
and the management of patients with irAEs. In contrast to other 
irAEs, rheumatic irAEs frequently persist over time, specifically 
inflammatory arthritis was persistent in almost 50% at most 
recent follow- up with a median of 9 months in a recent study.169 
Thus, irAEs represent a new spectrum of RMDs that rheumatol-
ogists should familiarise with. Interestingly, many of these mani-
festations, either frequent (arthritis, myositis, sicca syndrome) 
or more exceptionally reported (scleroderma, lupus) are also 
characteristics of graft versus host disease.242 Early consultation 
and strong collaboration between the referring oncologist, the 
treating rheumatologist, potentially other organ specialists and 
the patient are all required for optimal irAEs management.
These statements, being based almost entirely on low levels 
of evidence and on experts opinion, will undoubtedly require 
updating over the next few years, as new data emerge. Indeed, we 
expect that future oncological data will likely impact our irAEs 
therapeutic strategy. We also anticipate a better understanding 
of irAEs mechanisms and pathophysiology. Finally, multicentre 
collaborative efforts, prospective registries and randomised trials 
will help to define the optimal treatment strategies to relieve 
patient symptoms without altering oncological outcomes.
ReseARCH AGendA
 ► To better understand pathophysiology of rheumatic and 
systemic irAEs.
 ► To develop information on rheumatic and systemic irAEs for 
patients starting cancer immunotherapy.
 ► To define optimal glucocorticoid dose and duration 
according to the type of rheumatic and/or systemic irAE.
 ► To assess the effect of different immunomodulatory/
immunosuppressive agents already given before the start 
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of CPI therapy in pre- existing RMDs on the outcome of 
immunotherapy.
 ► To assess the effect of different immunomodulatory/immu-
nosuppressive agents administered for de novo rheumatic 
and systemic irAEs on the outcome of immunotherapy, using 
prospective registries.
 ► To develop well- designed trials on irAE management.
 ► To assess long- term evolution of rheumatic and systemic 
irAEs.
 ► To search for predictive factors for rheumatic and systemic 
irAEs.
 ► To revise CTCAE grading of rheumatic and systemic irAEs.
 ► To obtain insights on the initiation and propagation of clas-
sical rheumatic diseases.
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